LSALT peptide for COVID-19: real-time analysis of 2 studies

Download Image

Post

c19early.org

LSALT peptide for COVID-19

1 study with 61 patients

Serious outcome risk

LSALT peptide

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 LSALT peptide studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−407%

Mortality (1)−407%

Hospitalization (1)−7%

RCTs (1)−407%

Late (1)−407%

00.511.5+

← LSALT peptide
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


May 18 2024	Fowler et al., NCT04330690	A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization)
	Estimated 580 patient LSALT peptide late treatment RCT with results not reported over 2 years after estimated completion.
Mar 15 2024	Somayaji et al., BMJ Open, doi:10.1136/bmjopen-2023-076142	Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19)
	407% higher mortality (p=0.24) and 7% longer hospitalization (p=0.65). RCT 61 hospitalised moderate/severe COVID-19 patients showing no significant difference in clinical outcomes with intravenous LSALT peptide treatment.